AT-527(Bemnifosbuvir hemisulfate),AT-511 的半硫酸盐,是鸟苷核苷酸前体,是一种有效的具有口服活性的 HCV 病毒复制抑制剂。
此产品仅用于科学研究,我们不为任何个人用途提供产品和服务
AT-527(Bemnifosbuvir hemisulfate), a hemisulfate salt of AT-511, a guanosine nucleotide proagent, is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir hemisulfate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir hemisulfate has pangenotypic antiviral activity[1][2][3].
参考文献:
[1]. Steven S Good, et al. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus. PLoS One. 2020 Jan 8;15(1):e0227104.
[2]. Steven S Good, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021 Feb 8;AAC.02479-20.
[3]. Elina Berliba, et al. Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis. Antimicrob Agents Chemother. 2019 Sep 30;63(12):e01201-19.
AT-527(Bemnifosbuvir hemisulfate),AT-511 的半硫酸盐,是鸟苷核苷酸前体,是一种有效的具有口服活性的 HCV 病毒复制抑制剂。Bemnifosbuvir hemisulfate 有效抑制 SARS-CoV-2 (COVID-19) 感染 (EC90=0.47 μM)。Bemnifosbuvir hemisulfate 具有全基因型抗病毒活性。
没有评价数据